Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ITPRIPL2 antisense RNA 1 (ITPRIPL2-AS1) is a long non-coding RNA gene located opposite to the ITPRIPL2 protein-coding locus. As an antisense RNA, ITPRIPL2-AS1 is transcribed in a direction counter to its paired sense gene and can influence gene expression via mechanisms such as transcriptional interference, binding to regulatory DNA elements, or affecting chromatin structure and splicing events. Although its general class (antisense lncRNA) is known to modulate disease—especially cancer—by regulating sense transcript levels and pathways, direct molecular functions or therapeutic relevance for ITPRIPL2-AS1 remain limited. Observational data links RP11-626G11.3/ITPRIPL2-AS1 to glioma progression, implicating it in pathways regulating cell proliferation through microRNA and transcription factor modulation. No approved drugs or targeted therapies currently exist for this RNA.
No established drug mechanisms are reported targeting this RNA. However, antisense RNAs in general may be targeted by synthetic antisense oligonucleotides to modulate gene expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ITPRIPL2 antisense RNA 1 (ITPRIPL2-AS1).